Eton Pharmaceuticals/$ETON
1D1W1MYTD1Y5YMAX
Capital at risk
About Eton Pharmaceuticals
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
- Ticker
- $ETON
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 44
- Headquarters
- Deer Park, United States
- Website
- www.etonpharma.com
ETON Metrics
BasicAdvanced
$1.6B
133.36
$0.43
0.87
-
Price and volume
Market cap
$1.6B
Beta
0.87
52-week high
$66.37
52-week low
$14.27
Average daily volume
599K
Financial strength
Current ratio
1.52
Quick ratio
1.146
Long term debt to equity
43.278
Total debt to equity
62.735
Interest coverage (TTM)
4.52%
Profitability
EBITDA (TTM)
25.178
Gross margin (TTM)
61.41%
Net profit margin (TTM)
12.02%
Operating margin (TTM)
19.54%
Effective tax rate (TTM)
0.49%
Revenue per employee (TTM)
$2,400,000
Management effectiveness
Return on assets (TTM)
11.86%
Return on equity (TTM)
35.97%
Valuation
Price to earnings (TTM)
133.361
Price to revenue (TTM)
14.695
Price to book
34.66
Price to tangible book (TTM)
1,780.41
Price to free cash flow (TTM)
-5,790.221
Free cash flow yield (TTM)
-0.02%
Free cash flow per share (TTM)
-0.01
Growth
Revenue change (TTM)
81.49%
Earnings per share change (TTM)
-374.29%
3-year revenue growth (CAGR)
53.81%
3-year earnings per share growth (CAGR)
259.83%
What the Analysts think about ETON
Analyst ratings (Buy, Hold, Sell) for Eton Pharmaceuticals stock.
Analyst projections of the future price of Eton Pharmaceuticals stock.
Bulls say / Bears say
Commercial momentum is strong: Q2 2026 revenue increased 99% year over year to $37.6 million, adjusted EBITDA reached $16.2 million, and management raised full-year revenue guidance to more than $145 million. (Eton Pharmaceuticals)
Eton is expanding its rare-disease platform through new and recently launched products, including HEMANGEOL, DESMODA, IMPAVIDO, and the late-stage ASN-001 candidate, while also advancing Amglidia, ET-700, ET-800, and ZENEO hydrocortisone. (Eton Pharmaceuticals)
Profitability and cash generation are improving materially: Q2 net income was $11.6 million versus a $2.6 million loss a year earlier, and operating cash flow for the first six months of 2026 rose to $14.7 million from $10.0 million. (Eton Pharmaceuticals; SEC)
Revenue concentration remains a material risk: AnovoRx represented 90.4% of net product revenue in the first half of 2026, leaving Eton exposed to a single specialty-pharmacy distribution channel. (SEC)
International INCRELEX and GALZIN sales can dilute profitability: Eton said these non-U.S. sales generated negative gross margin, contributing to a decline in adjusted gross margin to 73% from 75% year over year in Q2. (Eton Pharmaceuticals)
Growth requires continued execution and upfront investment: Eton spent $15.1 million on investing activities in the first half of 2026, including $14 million for HEMANGEOL, while second-half R&D is expected to rise and cash stood at $26.8 million at June 30. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
ETON Financial Performance
Revenues and expenses
ETON Earnings Performance
Company profitability
Upcoming events
No upcoming events
ETON News
AllArticlesVideos
Funds containing ETON
AllUSDGBPEUR
Fund name | Fund size | $ETON weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.09% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.09% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.05% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.